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Abstract Exertional (exercise-induced) rhabdomyolysis is
a potentially life threatening condition that has been the
subject of research, intense discussion, and media attention.
The causes of rhabdomyolysis are numerous and can
include direct muscle injury, unaccustomed exercise,
ischemia, extreme temperatures, electrolyte abnormalities,
endocrinologic conditions, genetic disorders, autoimmune
disorders, infections, drugs, toxins, and venoms. The
objective of this article is to review the literature on
exertional rhabdomyolysis, identify precipitating factors,
and examine the role of the dietary supplement creatine
monohydrate. PubMed and SPORTDiscus databases were
searched using the terms rhabdomyolysis, muscle damage,
creatine, creatine supplementation, creatine monohydrate,
and phosphocreatine. Additionally, the references of papers
identified through this search were examined for relevant
studies. A meta-analysis was not performed. Although the
prevalence of rhabdomyolysis is low, instances still occur
where exercise is improperly prescribed or used as pun-
ishment, or incomplete medical history is taken, and
exertional rhabdomyolysis occurs. Creatine monohydrate
does not appear to be a precipitating factor for exertional
rhabdomyolysis. Healthcare professionals should be able to
recognize the basic signs of exertional rhabdomyolysis so
prompt treatment can be administered. For the risk of
rhabdomyolysis to remain low, exercise testing and pre-
scription must be properly conducted based on professional
standards.
1 Introduction
Exertional rhabdomyolysis continues to be reported in
healthy and patient populations despite efforts from the
medical and research communities to provide guidelines
about this potentially life-threatening condition. As an
example, in 2006, exertional rhabdomyolysis was reported
in a 12-year-old student who was forced to do[250 squat
jumps as punishment for talking in class [1]. While such
troubling cases appear in the literature, the reports of group
‘‘outbreaks’’ of rhabdomyolysis are even more discon-
certing. More than half of the McMinnville, Oregon, USA,
high school football players who entered immersion camp
in August of 2010 went to the hospital with rhabdomyol-
ysis following intense unaccustomed exercise [2, 3]; 12
were admitted and three had fasciotomies to treat com-
partment syndrome of the upper arm. Similarly, 12
University of Iowa football players were hospitalized with
rhabdomyolysis following intense exercise in January 2010
[4]. Historically, there have been other ‘‘outbreaks’’ of
rhabdomyolysis [5] and exertional (exercise-induced)
rhabdomyolysis [6, 7].
While many researchers/clinicians recognized exertional
rhabdomyolysis, numerous theories emerged from the
media and hundreds of comments were posted on the
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internet; many appeared determined to find a cause of the
‘‘outbreak’’ besides over-exertion/unaccustomed exercise.
Although many factors can influence the likelihood of
rhabdomyolysis, the dietary supplement creatine appeared
to be a popular focus of these theories and comments
despite a body of literature that demonstrates little or no
association between creatine supplements and rhabdomy-
olysis [8, 9]. Consequently, the purpose of this article is to
(1) review the literature on exertional rhabdomyolysis and
identify precipitating factors and (2) review the effects of
creatine supplementation on markers of muscle damage
and exertional rhabdomyolysis. PubMed and SPORTDis-
cus databases were searched using the terms rhabdomyol-
ysis, muscle damage, creatine, creatine supplementation,
creatine monohydrate, and phosphocreatine. Additionally,
the references of papers identified through this search were
examined for relevant studies. All articles in which indi-
viduals were ingesting creatine supplements were included.
A meta-analysis was not performed.
2 Rhabdomyolysis
2.1 Background
Rhabdomyolysis by definition means damage to skeletal
muscle. It was initially called ‘‘crush syndrome,’’ as it was
identified in 1940 during the London Blitz in patients
whose limbs were crushed. These patients survived their
initial injury, only to die of renal failure several days later.
The causes of rhabdomyolysis are numerous and can
include direct muscle injury (e.g., crush, bites, electrical
injuries, repetitive blows), unaccustomed exercise (espe-
cially with eccentric/muscle-lengthening contractions),
ischemia (e.g., tourniquets, immobilization, compartment
syndrome), extreme temperatures, electrolyte abnormali-
ties (e.g., hypokalemia, hyponatremia), endocrinologic
conditions (e.g., diabetic ketoacidosis, hypothyroidism),
genetic disorders (e.g., metabolic myopathies, muscular
dystrophy, pseudometabolic myopathy), autoimmune dis-
orders (e.g., polymyositis, overlap myositis), infections
(e.g., Staphylococcus aureus sepsis, viral myositis, necro-
tizing fasciitis), drugs (e.g., statins), toxins (e.g., hemlock,
toxic mushrooms), and venoms (e.g., bites, stings) [10].
Regardless of the cause, damage to the muscle results in
increased intracellular calcium, which in turn activates
proteases and causes necrosis. As the focus of this review is
exertional rhabdomyolysis, the reader is directed elsewhere
for a complete description of the etiology and non-exercise
causes of rhabdomyolysis [10, 11].
Delayed-onset muscle soreness (DOMS) experienced a
day or so after strenuous unaccustomed exercise is an
indicator of muscle damage and signifies a very mild
form of rhabdomyolysis. This becomes clinically relevant
when there is extensive damage to the muscle fibers, the
pain is severe, and large amounts of muscle proteins are
released into the blood stream (e.g., creatine kinase [CK],
lactate dehydrogenase [LDH], and myoglobin). While
other proteins are cleared by the reticulo–endothelial
system, myoglobin is cleared by the kidneys. Myoglobin,
and likely other proteins, can precipitate in the kidney or
be directly nephrotoxic (oxidative stress), resulting in
acute renal failure that—if left untreated—could be life
threatening. A cardinal sign that an individual should seek
immediate treatment is dark-colored urine (pigmenturia
[brown, red, tea, or cola colored]); this occurs because the
kidneys are clearing myoglobin from the blood and it
spills over into the urine. However, myoglobinuria with-
out rhabdomyolysis has been described in ultra-marathon
runners [12], which further complicates diagnosis and
treatment.
It can be difficult to know when an individual crosses
the line from a normal physiological response to exercise to
clinically relevant rhabdomyolysis. Blood CK levels
increase in the hours following muscle damage and remain
elevated for several days. CK is easily assessed in the
serum and is a sensitive, but not specific, marker of muscle
tissue damage. While some would argue that CK values
[15,000 IU/l are predictive of renal impairment, this is
likely population specific. For instance, we showed post-
exercise CK[ 2000 IU/l (n = 111) and [10,000 IU/l
(n = 51) in volunteers who performed 50 maximal
eccentric contractions of the elbow flexors. Despite the
markedly increased CK of these research volunteers, none
experienced visible myoglobinuria or required treatment
for impaired renal function [13]. Kenney et al. [14]
examined data from military recruits in basic training
(n = 499) and, although none developed clinical exertional
rhabdomyolysis, mean CK values were 734, 1226, and
667 IU/l on days 3, 7, and 14 post-exercise (normal adult
values: males 52–336 IU/l; females 38–176 IU/l). The
highest CK reported was 35,056 IU/l. The authors sug-
gested that because CK levels consistently exceeded nor-
mal values,[50 times the traditional upper limit would be
more specific for this population. Thus, exertional muscle
damage produced by eccentric exercise in healthy indi-
viduals can cause profound CK and myoglobin elevations
without renal impairment, and elevated CK is likely a
population-specific bio-marker.
Treatment involves intravenous fluids with or without
bicarbonate to alkalinize the urine for 3–7 days, with the
goal to dilute myoglobin and other potential nephrotoxic
substances. The damage to muscle may also produce
myoedema, leading to compartment syndrome where the
connective tissue surrounding the muscle restricts the
swelling, increases the pressure, and limits blood flow to
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the muscle, causing a ‘‘vicious cycle’’ of tissue necrosis.
Treatment of acute compartment syndrome involves cut-
ting the connective tissue (fasciotomy) to allow the muscle
to swell without restriction, thus maintaining blood flow.
When rhabdomyolysis involves the development of acute
renal failure or compartment syndrome, it becomes clini-
cally relevant [15]. Of interest to many clinicians and
practitioners is the issue of ‘‘return to play/duty/physical
activity.’’ A full discussion is beyond the scope of this
paper. Although there are no standard guidelines, we refer
the reader to the excellent review by O’Connor et al. [16],
who suggest that three issues must be addressed: (1)
recurrence risk, (2) timeline of safe return, and (3) potential
restrictions.
Exertional or exercise-induced rhabdomyolysis has been
reported in case studies following excessive unaccustomed
exercise in several different scenarios including, military
training [17–27], physical education class [6], moun-
taineering [28], supervised [29–32] and unsupervised
[33–37] strenuous training, and marathon running
[12, 38–41]. Several factors can increase the risk of exer-
tional rhabdomyolysis, including an increase in exercise
intensity/duration or using different muscle groups (unac-
customed strenuous exercise), muscle contraction type
(eccentric/lengthening[ concentric), infection, medication
use, dietary factors (e.g., hydration), environmental factors
(extremes of heat and cold), sex (males[ females), and
genetic factors (reviewed by Huerta-Alardin et al. [11]).
Potential precipitating and mitigating factors in exertional
rhabdomyolysis are discussed in the following sections.
2.2 Resistance vs. Endurance Exercise
Performance of unaccustomed exercise is the primary
determinant of exertional rhabdomyolysis. Most often this
occurs in trained individuals who dramatically increase
their training workout, train a different muscle group, or
use a different contraction type, sometimes when encour-
aged and motivated to overexert themselves by a coach or
personal trainer [32]. In untrained individuals, this can
occur during the start of an exercise training program,
especially when a personal trainer or coach encourages
overexertion [32].
The muscle contractions that cause the most muscle
damage are those where the muscle lengthens as it is
attempting to contract (also referred to as eccentric in
classical literature), for example lowering a weight during
a biceps curl. In the gym, these contractions are referred to
as ‘‘negatives.’’ High-force (high-resistance) lengthening
contractions place strain on the muscle fibers and cause
damage to protein structure, releasing muscle proteins into
the circulation [42]. Some aerobic exercises can be biased
toward lengthening contractions, such as downhill running
[43]. In the laboratory, we use such contractions to study
mild forms of rhabdomyolysis (not clinically relevant)
[13, 44–46]. We have found that performance of laboratory
eccentric exercise results in DOMS/pain, prolonged losses
in strength and range of motion, and release of muscle
proteins into the circulation [47].
Endurance (aerobic) exercise typically does not result in
clinically relevant rhabdomyolysis. While rare instances of
rhabdomyolysis occur in marathon runners [40], the degree
to which renal failure is a consequence of rhabdomyolysis
or occurs independent of rhabdomyolysis (i.e., severe
dehydration, hyperhydration, or hyponatremia) is not
known. McCullough et al. [48] examined kidney function
in 25 marathon runners 4 weeks before, immediately after,
and 24 h after a race. Of the runners, 40% showed evidence
of acute kidney injury (based on increase in serum crea-
tinine) immediately following the race, which resolved in
the next 24 h. Data from the Comrades Marathon in South
Africa showed that in an 18-year period (1969–1986), only
19 cases of acute renal failure were reported, whereas the
total number of participants ranged from 2000 to 10,000
per year [49]. In cases of marathon running, it appears that
renal failure can occur without a profound increase in
muscle proteins in the circulation, likely due to varying
combinations of dehydration, superimposed illness,
hyperthermia, and drugs leading to lowered renal perfusion
[49]. For example, MacSearraigh et al. [50] reported nine
cases of acute renal failure in the Comrades Marathon;
several runners had taken analgesics and four may have
had a viral or bacterial infection. Another report from the
Comrades Marathon [49] found four cases of acute renal
failure; two had an infection prior to the race and all four
ingested analgesics prior to the race. Analgesics, particu-
larly non-steroidal anti-inflammatory drugs (NSAIDs), can
reduce renal perfusion, leading to a depressed glomerular
filtration rate [51]. Furthermore, one case report described
a marathon runner who had taken NSAIDs before the race
for a viral infection and who collapsed at the finish line in
cardiac arrest; he was later diagnosed with a muscle
myopathy [52]. Several factors may together create a sit-
uation that increases the risk for acute renal failure in
marathon runners, including pre-existing viral or bacterial
infection and/or use of analgesics and NSAIDs.
2.3 Effects of Hydration
Clinically relevant rhabdomyolysis is often associated with
unaccustomed, strenuous exercise in a hot environment,
especially where dehydration is a factor [15]. Reduced
hydration impairs the ability of the kidneys to clear myo-
globin and other potential myotoxic substances, conse-
quently increasing the risk of myoglobin precipitation,
renal cast formation, and possibly local factors intrinsic to
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the kidney such as oxidative stress (ischemia–reperfusion),
increasing the risk for renal failure. Although a risk factor,
dehydration does not have to be present for clinically rel-
evant rhabdomyolysis to manifest [31, 32]. Somewhat
paradoxically, rhabdomyolysis can also occur in the pres-
ence of hyperhydration during exercise, wherein associated
hyponatremia is a likely etiological factor. Of 400 starters
of the 2009 Western States 161-km Endurance Run, five
presented with rhabdomyolysis and hyponatremia [53].
Although this small number of cases seems inconsequen-
tial, clinicians must be aware that the treatments for
rhabdomyolysis (intravenous isotonic fluid) and hypona-
tremia (water restriction or intravenous concentrated/hy-
pertonic fluid) are incongruous. The relationship, causal or
independent, between hyponatremia and rhabdomyolysis is
currently unknown. It is unclear how over-hydration leads
to a higher risk of rhabdomyolysis, but hyponatremia is
clearly a key factor.
2.4 Sex Differences
Rhabdomyolysis occurs more frequently in men than
women. Alpers and Jones [54] reported that, of 63 cases of
exertional rhabdomyolysis in military trainees, 88.9% were
men, although the overall population of trainees without
rhabdomyolysis was 75.5% men. Using our laboratory
exercise regimen to induce a mild form of rhabdomyolysis,
we found that a higher percentage of women than of men
experienced profound ([70%) loss in strength immediately
after high-force eccentric exercise [55]. However, men
showed greater average increases in CK, and more men
than women were high CK responders [55]. Reportedly,
men usually show a greater immune response to eccentric
contractions [56]. Although there is currently no explana-
tion for these sex differences, some models indicate a
protective role of estrogen [44, 56].
2.5 Children and Adolescents
Rhabdomyolysis in children is rare. One published case
describes a 17-year-old boy who presented with myalgia,
weakness, and dark urine 6 days following the start of
high-school football practice [57]. Myalgia was first noted
on the evening after the first practice, but the boy continued
the practice sessions for the next 5 days. Serum CK was
96,000 U/l, and urine dipstick was positive for the presence
of blood. Lin et al. [6] presented a brief report of 119 high-
school students aged 17–18 years who performed 120
push-ups in 5 min as part of a physical education class. The
post-exercise serum CK values ranged from 55 to
174,260 U/l. Many of the students developed muscle pain
and dark urine 2–4 days after the exercise. Most were
treated with oral hydration, but 20 students were
hospitalized. We reported a case of an 18-year-old football
player following a supervised practice session led by the
team’s strength and conditioning coach [31]. The day after
this session, the player experienced extreme pain and dark
urine and sought treatment at a local emergency depart-
ment. Hospitalization resulted in a diagnosis of rhab-
domyolysis based on myoglobinuria, muscle pain, and
extremely elevated circulating CK values ([130,000 U/l).
Following 8 days of hospitalization with intravenous fluids,
the patient recovered without complications. The strength
coaches, athletic trainer, and team physician missed the
classic signs of rhabdomyolysis (extreme pain and brown
urine) and did not recommend that the player get treatment.
We also reported [29] exertional rhabdomyolysis in a
12-year-old boy who participated in an indoor physical
education class where excessive (between 250 and 500)
repetitive squat jumps were performed as punishment for
talking in class. The boy, who reported intense muscle
soreness in the thighs and dark urine 2 days post-exercise,
was brought to the emergency room by his parents. His
serum CK was 92,115 U/l, and urinalysis indicated the
presence of blood and protein. He was transferred to
another hospital that evening, admitted, and treated for
7 days. His serum CK rose to 244,006 U/l at 4 days post-
exercise. The boy was discharged after 7 days of hospi-
talization, at which time CK was 9101 U/l. The other
children in the class were not hospitalized.
2.6 Other Precipitating Factors
Many of the case studies cited above illustrate that only a
small percentage of individuals exposed to the same
exercise conditions experience rhabdomyolysis. For
example, one report stated there were 22.2 cases of exer-
tional rhabdomyolysis per 100,000 military trainees per
year [54]. Another case in point is the Iowa football team
mentioned in Sect. 1. Only 13 of about 100 players who
trained that day were hospitalized and treated for clinically
relevant rhabdomyolysis. In our laboratory, where we
induce a safe form of rhabdomyolysis, a small percentage
of subjects are high responders [58]. These high responders
experience severe muscle pain, profound swelling, extreme
muscle weakness, and/or large elevations of CK in the
blood. There are known genetic factors that will predispose
a person to rhabdomyolysis, such as sickle cell trait
[59–61], carnitine palmitoyltransferase (CPT) deficiency,
and McArdle disease [15]. Although a genetic disorder
may explain episodes of recurrent rhabdomyolysis after
minimal to moderate exertion, they are not typically
associated with the first bout of exertional rhabdomyolysis
after strenuous unaccustomed exercise. Given the huge
variance in CK elevation and muscle damage seen in
response to controlled eccentric exercise performed in the
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laboratory setting [42, 46, 47, 56, 62, 63], it is likely that
polygenetic factors lead to inter-individual rhabdomyolysis
risk as opposed to monogenetic disorders such as fatty acid
oxidation defects (e.g., CPT2 deficiency) or glycogen
storage diseases (e.g., McArdle disease). We [64, 65] and
others [66–68] have found that certain single nucleotide
polymorphisms (SNPs) may be associated with a high
response. SNPs are variations in a single nucleotide in the
DNA. There are thousands of these variations, and typi-
cally SNPs exert an effect in coordination with other SNPs.
Thus, it is likely that many SNPs may contribute to making
an individual more susceptible to exertional muscle dam-
age (polygenetic risk variance). Although most cases of
exertional rhabdomyolysis are likely due to polygenetic
risk and overexertion (often under external influence to
push beyond the intrinsic signals telling one to stop—i.e.,
not ‘‘listening to the body’’), it is important to identify the
small fraction of patients who present with rhabdomyolysis
who have an underlying monogenetic metabolic myopathy.
3 Metabolic Myopathies and Rhabdomyolysis
3.1 Overview of Metabolic Myopathies
Metabolic myopathies are genetically determined inborn
errors of metabolism that impair the bioenergetic pathways
responsible for fat, amino acid, and mitochondrial or car-
bohydrate oxidation. Under circumstances of cellular
metabolic stress, these disorders can result in an energy
crisis (low energy charge) in the cell that can lead to
rhabdomyolysis. It is important to note that metabolic
myopathies are a rare cause of exertional rhabdomyolysis
but are nevertheless important to recognize since important
preventive and acute treatment strategies exist as does
genetic counseling for patients and their families.
In addition to the inborn errors of metabolism, several of
the muscular dystrophies can present with a ‘‘pseu-
dometabolic’’ pattern where physical activity can trigger
exertional and post-exertional myalgias with rhabdomyol-
ysis, hyperCKemia and eventually myoglobinuria [69].
One clue to an underlying genetic muscular dystrophy is
muscle weakness and hyperCKemia that remain even after
resolution of the rhabdomyolysis event, whereas the inborn
errors of metabolism usually result in full recovery of
strength and normalization of hyperCKemia, with the
exception of McArdle disease where hyperCKemia is a
chronic feature.
3.2 Fatty Acid Oxidation Defects
The most common fatty oxidation defects are related to
mutations in CPT2, very long chain acyl-CoA
dehydrogenase (VLCAD), and trifunctional protein (TFP)
proteins. These patients can present with a rhabdomyolysis
phenotype (e.g., myalgia, pigmenturia) precipitated by
longer-term exercise, fasting, or concomitant illness. The
diagnosis is best investigated by acyl-carnitine profiling in
blood or fibroblast culture; however, in some of the milder
cases the defect can only be seen only during a metabolic
crisis or with superimposed stress (fasting or exercise).
During an acute bout of rhabdomyolysis in b-oxidation
defects, free fatty acid levels in the serum are often high
and ketones are low (b-OH butyrate). Acyl-carnitine pro-
filing in serum can often be used to target the most likely
genetic mutational analysis, and, once a specific defect is
suspected, a targeted mutational analysis of the gene in
question can be performed (reviewed by van Adel and
Tarnopolsky [70]).
The best treatment for these disorders is to avoid pre-
cipitating factors such as exercising in the fasted state or
with a superimposed infection. A high-carbohydrate diet is
beneficial [71], and although carbohydrate supplementation
immediately prior to and during exercise is logical and
anecdotally of significant benefit to patients, one study
suggested that it was of limited benefit compared with
intravenous glucose [72]. Nevertheless, given the absence
of side effects and the conceptual basis behind the strategy,
carbohydrate consumption during exercise is worth evalu-
ating on a patient-by-patient basis. Supplementation with
medium-chain triglyceride oil is not likely to be of any
significant benefit and although riboflavin has not been
definitely shown to be of benefit, it is essentially non-toxic
and some patients may consider a trial of 100 mg twice
daily. Another strategy, using the anapleurotic substance
triheptanoin, may be of some benefit, although availability
of this substance is a practical challenge; clinical studies
are underway. More recently, there is some evidence that a
peroxisome proliferator-agonist receptor (PPAR) agonist
called bezafibrate (fibric acid derivative used for hyper-
triglyceridemia) can enhance beta oxidation in vitro [73]
but likely only in *25% of cases [74], and studies are
underway to see whether this helps patients with fatty acid
oxidation defects. Certainly, if a patient with a fat oxida-
tion defect had hypertriglyceridemia requiring medical
therapy, a fibrate would be a drug of first choice.
3.3 Disorders of Carbohydrate Metabolism/
Glycogen Storage Disease
Patients with defects in glycolysis or glycogenolysis usu-
ally experience muscle cramps with higher-intensity
activity, occasionally followed by rhabdomyolysis and
pigmenturia. The cramps are often quite painful and usu-
ally resolve with rest for several minutes. In the glyco-
genolytic defects (but not the glycolytic defects), there is a
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‘‘second wind phenomenon’’ whereby the exercise feels
easier after a period of reduced-intensity exercise; this is
due to the delivery of blood-born substrates. Occasionally,
swelling can ensue within the muscle and lead to com-
partment syndrome. The most common glycogen storage
disease affecting muscle is McArdle disease, which is due
to a genetic defect in myo-phosphorylase, and several
hundred mutations have been documented. Rare cases of
phosphorylase b kinase deficiency have been documented,
but the clinical phenotype is usually milder. The second
most common defect is a deficiency of phosphofructoki-
nase (PFK), which causes a similar clinical picture to that
of McArdle disease and may also be associated with
hemolysis and does not show the second wind phenomenon
(for a review, see van Adel and Tarnopolsky [70]).
Patients with glycogenolytic and glycolytic defects will
have no (or very attenuated) increase in lactate in response
to a semi-ischemic or non-ischemic forearm exercise and
will show enhanced ammonia rise [75]. The increase in
ammonia is due to an increased reliance on the adenylate
kinase and the adenosine monophosphate (AMP)–deami-
nase pathway as a cellular attempt to provide an alternative
source of anaerobic adenosine triphosphate (ATP). A nor-
mal forearm exercise test rules out essentially all of the
glycolytic and glycogenolytic defects except for phospho-
rylase b kinase deficiency, where the blunting of lactate
rise is best seen with aerobic exercise [76]. A muscle
biopsy can be checked for specific phosphorylase or PFK
enzyme activity at the histochemical level. Periodic acid–
Schiff (PAS) staining usually shows an increase in glyco-
gen, and electron microscopy shows a non-specific increase
in non-membrane-bound glycogen in the glycolytic and
glycogenolytic defects. Although CK increases acutely
with rhabdomyolysis, most patients with McArdle disease
will have chronically elevated CK activity in blood and
some will have myogenic hyperuricemia and develop gout
(due to the flux through the adenylate kinase ? AMP
deaminase ? xanthine oxidase pathway).
Paradoxically, the most effective treatment for McArdle
disease is consistent exercise training [77, 78], and exercise
tolerance is clearly enhanced with pre-exercise carbohy-
drate ingestion [79]. Exercise needs to be undertaken in the
fed state except in PFK deficiency, where exercise should
be completed in the fasted state because carbohydrate
feeding attenuates lipolysis and makes PFK-deficient
patients worse [80]. Carefully supervised and gradually
progressive exercise significantly improves exercise
capacity in patients with McArdle disease [78], and we also
have seen very dramatic results with carefully planned and
gradually progressive exercise in our patients with McAr-
dle disease. One study showed that low-dose creatine
monohydrate enhanced power output in patients with
McArdle disease [81]. High-dose creatine supplementation
actually impaired exercise capacity in patients with
McArdle disease [82], possibly through an inhibition of
PFK at the higher creatine dose levels. Several studies have
clearly shown that pre-exercise carbohydrate supplemen-
tation can enhance exercise energy output because the
plasma glucose entering the cell can be immediately oxi-
dized for energy since it does not need to first form
glycogen before glycolytic flux. Other strategies such as
the higher protein diet and pyridoxine supplementation
have been evaluated and have not been particularly effec-
tive in clinical trials but could be considered in isolated
cases [83].
3.4 Mitochondrial Myopathies
The mitochondrial myopathies are those defects due to
primary genetic defects affecting components of the elec-
tron transport chain (ETC). Given that mitochondrial dis-
eases lead to aerobic energy deficits (low maximal oxygen
consumption [VO2max]), most patients have moderate to
severe exercise intolerance. Although rhabdomyolysis as a
primary manifestation of a mitochondrial myopathy is rare,
those with rhabdomyolysis present under metabolic con-
ditions similar to those in patients with fatty acid oxidation
defects (fasting, prolonged exercise). Many mitochondrial
DNA (mtDNA) and nuclear DNA (nDNA) mutations cause
mitochondrial cytopathies, but only a few have been
associated with exercise-induced rhabdomyolysis. The
most common mutations that lead to rhabdomyolysis/
myoglobinuria are the cytochrome b mutations [84];
however, rhabdomyolysis/myoglobinuria can be seen in
patients with mitochondrial myopathy due to mutations in
other mtDNA genes, including cytochrome c oxidase
subunits [85], multiple mtDNA deletions [86], leu-transfer
RNA (tRNA) (3243 A[G; 3260 A[G) [87], and ile-tRNA
[88], and a mutation has been found in a mitochondrial
iron-sulfur cluster assembly (ISCU) protein [89].
The workup of patients with mitochondrial cytopathy is
complex and beyond the scope of this review; however,
readers are directed towards several review papers for a
more in-depth discussion [70, 90]. In brief, plasma lactate
is elevated in approximately 65% of patients with mito-
chondrial cytopathies; however, care must be taken to
ensure that the sample is collected and transported on ice to
avoid false positives. Plasma amino acid analysis may
show an elevation of alanine. Urine organic acid analysis
may show elevations of lactate, pyruvate, malate, or
3-methyl glutaconic acid. Definitive testing requires a
muscle biopsy with light and electron microscopic evalu-
ation. Common light microscopic abnormalities include
ragged red fibers and cytochrome c oxidase negative fibers.
Electron microscopic analysis often shows pleomorphism
and increased number of mitochondria that may contain
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paracrystalline inclusions (crystallized mitochondrial CK).
Enzymatic activity of the ETC enzymes often helps iden-
tify a specific mutation in one of the complexes or multiple
defects sometimes seen in the tRNA or ribosomal RNA
defects. Genetic analysis for specific point mutations is best
done on muscle-derived DNA; mtDNA deletions are
rarely, if ever, seen in white blood cell-derived DNA
samples and ideally should be run from muscle biopsy-
derived mtDNA. Although mutations in mtDNA are well
described [70], an increasing number of mutations have
been identified in nDNA, and the discovery of the ISCU
mutation [88, 89] represents a nuclear gene defect associ-
ated with rhabdomyolysis.
The treatment of mitochondrial myopathies is complex
and evolving, but most patients are placed on a ‘‘mito-
chondrial cocktail’’ of co-factors, antioxidants, and alter-
native energy sources (i.e., creatine monohydrate) [91, 92].
We also measure plasma carnitine levels and replace
deficiencies to avoid secondary fatty acid deficiency-like
triggering of rhabdomyolysis during exercise. Strategies
such as avoiding unaccustomed exercise during fasting or
concurrent illness are also recommended. Perhaps the most
effective therapy is carefully titrated endurance and resis-
tance exercise training to raise the threshold for triggering
symptoms of weakness, muscle fatigue, and rhabdomyol-
ysis [93].
3.5 Statin Myopathies
Statins are effective lipid-lowering drugs that block the
enzyme 3-hydroxy-3 methylglutaryl co-enzyme A
(HMG-CoA) reductase. The statins are a very safe group
of medications as a whole, but myalgias can be seen in
up to 5% of all patients taking the medication, and
*0.1% of all users will experience rhabdomyolysis,
defined as a CK elevation to[10 times the upper limit
of normal [94].
The cause of statin myopathies is unclear, and many
theories have been put forth, including reduced coenzyme
Q10 synthesis, lower cholesterol/altered sarcolemmal flu-
idity, reduced phrenylation of structural proteins, and
activation of apoptosis. Genetic predispositions for the
statin myopathies such as the metabolic myopathies [95]
and polymorphisms in LPIN 1 [96] are likely. Acute
exercise-induced hyperCKemia appears to be enhanced in
patients receiving statins, and this is true for both endur-
ance- and resistance-type exercise and can even occur in
well-trained athletes [94]. Fortunately, some people can
avoid the use of statins and other hypercholesterolemic
medications with exercise training and dietary interven-
tions and obviate the potential interaction between statins
and exercise by eliminating the need for the statin.
4 Creatine Supplementation and Exertional
Rhabdomyolysis
4.1 Creatine Metabolism and Supplementation
Creatine is a non-essential nutrient that is consumed in the
diet and produced in the body from amino acids. Approx-
imately 95% of the body’s creatine is stored in skeletal
muscle as creatine or phosphocreatine, where it is involved
in energy metabolism. Both creatine and phosphocreatine
are non-enzymatically degraded to creatinine and excreted
in the urine. High-intensity exercise tasks (e.g., 100-m
sprint, one down in gridiron football, one set of squats) rely
heavily on muscle phosphocreatine to resynthesize ATP to
support muscle contraction. Skeletal muscle phosphocre-
atine and creatine content can be increased about 20% with
oral creatine ingestion using either a brief high-dose pro-
tocol (about 20 g/day for 5 days) [97] or a longer-term
lower-dose protocol (about 3 g/day for about 30 days) [98].
Improved exercise performance, particularly high-intensity
exercise, following creatine supplementation, is a consis-
tent finding in the literature (reviewed by Gualano et al. [8],
Bemben and Lamont [99], Branch [100], and Rawson and
Volek [101]) and occurs with both the high dose (reviewed
by Gualano et al. [8]) and lower-dose [102, 103] supple-
mentation protocols. Creatine exerts an ergogenic effect
through multiple mechanisms involving pre-, during, and
post-exercise enhancements. These include increased pre-
exercise muscle creatine and phosphocreatine [97, 98] and
glycogen [104–106] (reviewed by Volek and Rawson
[107]), faster phosphocreatine re-synthesis during recovery
periods [108, 109], reduced post-exercise inflamma-
tion/muscle damage [110–115], increased expression of
growth factors [116–120], faster post-exercise strength
recovery [112], lower protein degradation [121], and
increased training volume [122] (reviewed by Rawson and
Persky [123]). Additionally, creatine supplementation has
been shown to improve muscle function in various patient
populations (e.g., dystrophy, aging) (reviewed by Gualano
et al. [8], Kley et al. [124], Rawson and Venezia [125], and
Tarnopolsky [126]) and has an excellent safety profile
(reviewed by Gualano et al. [8] and Persky and Rawson
[9]).
4.2 Creatine Supplementation, Muscle Damage,
and Rhabdomyolysis
The first connection between creatine supplementation and
rhabdomyolysis was likely made in 1997, when three
National Collegiate Athletic Association (NCAA) wrestlers
died within a 2-month period (official causes of death were
unknown, hyperthermia, and rhabdomyolysis) [127]. Each
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had been using rapid weight loss techniques (e.g., intense
exercise wearing vapor-restrictive clothing while in a
sauna) to qualify for a lower weight class. This event was
covered by major media outlets and forced the NCAA to
reevaluate weigh-in procedures, weight class limits, and
weight loss tactics. Creatine was at the center of the storm,
although the Centers for Disease Control (CDC) and the
US FDA did not implicate creatine. In fact, the often cited
article published in Morbidity and Mortality Weekly
Reports that described the wrestler’s weight loss tactics and
subsequent deaths does not even mention the word creatine
[127]. However, a myth was born, and the erroneous
connection between creatine supplementation and rhab-
domyolysis still exists today.
Oddly, few publicly questioned why athletes struggling
to lose weight would be ingesting a dietary supplement
known to increase body mass. Additionally, few pointed to
ephedrine, a banned substance that is remarkably under-
reported in NCAA athletes compared with non-NCAA
athletes and a seemingly ideal supplement for wrestlers
(but not condoned by the authors) as it decreases appetite,
increases metabolic rate, and decreases body mass (re-
viewed by Rawson and Clarkson [128]). Ephedrine
increases heart rate and blood pressure in young adults
[129], has a higher absorption rate and peak plasma con-
centration when combined with dehydration [130], can be
cardio-toxic [131], and was clearly being used by wrestlers
at the time [132]. When the 2010 rhabdomyolysis ‘‘out-
breaks’’ happened in Oregon and Iowa, and despite more
than 10 years of research on creatine supplementation,
muscle damage, and rhabdomyolysis, creatine was impli-
cated again in spite of little to no evidence to support the
claim.
4.3 Creatine Supplementation and Resting Markers
of Muscle Damage
Both Robinson et al. [133] and Mihic et al. [134] reported
no effect of high-dose short-term (20 g/day for 5 days) and
low-dose longer-term (3 g/day for 8 weeks) creatine sup-
plementation on blood CK activity in physically unstressed
subjects. Additionally, Robinson et al. [133] found no
increase in serum CK activity in a group that performed
8 weeks of resistance training in addition to creatine
ingestion (20 g/day for 5 days followed by 3 g/day for
8 weeks). Both groups reported no changes in renal func-
tion. Schilling et al. [135] and Kreider et al. [136] reported
no differences in resting serum LDH and CK, respectively,
in elite strength/power athletes. Following a high-dose
creatine loading protocol, athletes in these studies ingested
maintenance doses of creatine 5–10 g/day for 0.8–4 years
[135, 136]. Collectively, these data indicate that creatine
supplementation has no effect on bio-markers of muscle
damage. The effects of creatine supplementation on
markers of muscle damage at rest are summarized in
Table 1 [133–136].
4.4 Creatine Supplementation, High-Force
Eccentric Exercise, and Markers of Exercise-
Induced Muscle Damage
The effects of creatine supplementation on exercise-in-
duced muscle damage following high-force eccentric
exercise have been reported by four groups
[46, 112, 137, 138]. Rawson et al. [46] first demonstrated
that creatine supplementation (20 g/day for 5 days) had no
negative effect on post-exercise serum CK and LDH,
strength, range of motion (ROM), swelling, and DOMS.
The protocol used by Rawson et al. [46] (50 maximal
eccentric contractions) is known to produce marked muscle
damage of the elbow flexors [47]. Later, Cooke et al. [112]
tested the effects of creatine supplementation (0.3 g/kg/day
for 5 days followed by 0.1 g/kg/day for 14 days) on the
response to eccentric exercise of the lower body (four sets
of ten leg presses, leg extensions, and leg curls with 120%
concentric 1 repetition maximum [1-RM]) and found
reduced post-exercise CK and LDH (trend) and increased
recovery of strength. Using a similar exercise stress (seven
sets of ten eccentric leg extensions at 150% concentric
1-RM), Rosene et al. [138] noted that creatine ingestion
(20 g/day for 7 days followed by 6 g/day for 23 days) had
no effect on CK, LDH, ROM, DOMS, strength, or force on
day 8 but improved isometric force production on day 30
after a second exercise bout. Finally, McKinnon et al. [137]
reported that creatine supplementation (40 g/day for 5 days
followed by 10 g/day for 5 days) ingested for 5 days
before and 5 days following a damaging exercise protocol
(six sets of ten eccentric contractions of the elbow flexors
at 75, 90, and 120 per second) had no effect on isometric
strength recovery or DOMS. Of note is that even under the
most stressful exercise conditions (high-force eccentric
exercise), and whether large (knee extensors and flexors) or
small (elbow flexor) muscle mass was involved, creatine
did not exacerbate the response to this severe muscular
challenge. The effects of creatine supplementation on
exercise-induced muscle damage following various
eccentric exercise challenges are summarized in Table 1
[46, 112, 137, 138].
4.5 Creatine Supplementation, Endurance Exercise,
Sprints, and Markers of Exercise-Induced
Muscle Damage
Others have examined the effects of creatine supplemen-
tation following stressful endurance or sprint exercise (road
race, triathlon, repeated sprints) [110, 111, 113, 114]. For
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instance, Santos et al. [114] reported that 5 days of creatine
supplementation (20 g/day) prior to a 30-km race reduced
post-exercise CK (19%), prostaglandin-E2 (PGE2) (61%),
tumor necrosis factor (TNF)-a (34%), and completely
dampened the increase in LDH. Bassit et al. [110, 111]
evaluated the effects of creatine supplementation (20 g/day
for 5 days) following half- and full-distance Ironman
triathlons. It was noted that the post-race increase in TNF-
a, PGE2, interferon (IFN)-a, and interleukin (IL)-1-b was
blunted following the half-distance Ironman triathlon, as
was the post-race rise in CK, LDH, aldolase, glutamic
oxaloacetic acid transaminase (GOT), and glutamic pyru-
vic acid transaminase (GPT) following the full-distance
Ironman triathlon in creatine-supplemented athletes. While
inflammatory markers are not used clinically in the diag-
nosis of rhabdomyolysis, they are well-established markers
of post-exercise inflammation. Finally, Deminice et al.
[113] reported that creatine supplementation (0.3 g/kg/day
for 7 days) blunted the post-exercise (six 35-m sprints)
increase in c-reactive protein (CRP), TNF-a, and LDH
despite increased maximum, mean, and minimum power
production. Overall, the available data strongly suggest that
creatine supplementation prior to an endurance exercise
challenge reduces muscle damage and inflammation in
athletes, both of which would predict a lower risk of
rhabdomyolysis, not a higher risk. The effects of creatine
supplementation on endurance exercise-induced muscle
damage are summarized in Table 1 [110, 111, 113, 114].
4.6 Creatine Supplementation, Resistance Exercise,
and Markers of Exercise-Induced Muscle
Damage
Several groups have investigated the effects of creatine
supplementation on recovery from intense resistance
exercise that is more typical of real-world training
[115, 139, 140]. Rawson et al. [140] examined the effects
of creatine supplementation (0.3 g/kg for 5 days; followed
by 0.03 g/kg for 5 days) on recovery from a high-intensity
squat workout (five sets of 15–20 reps at 50% 1-RM) and
found no effect of the creatine on post-exercise strength,
serum CK and LDH, ROM, swelling, and DOMS.
Machado et al. [139] found no difference in post-exercise
CK between creatine- (20 g/day for 5 days) and placebo-
supplemented subjects following three sets of ten repeti-
tions of five exercises performed at 75% of 1-RM.
Recently, Veggi et al. [115] showed that creatine supple-
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CK and DOMS and decrease in ROM to a greater extent
than a placebo following repeated bouts of resistance
exercise (four sets of biceps curls at 75% 1-RM). Together,
these papers indicate that creatine supplementation does
not disrupt and may enhance recovery from resistance
exercise with both concentric and eccentric contractions.
The effects of creatine supplementation on resistance
exercise-induced muscle damage are summarized in
Table 1 [115, 139, 140].
4.7 Creatine Supplementation, Muscle Injury,
and Muscle Dysfunction
Several open-label trials of the effects of creatine supple-
mentation on muscle cramps, muscle tightness, muscle
strains, injuries (contact and non-contact), missed prac-
tices, and players lost for the season in collegiate athletes
have been published. In comparison with non-creatine
users, creatine users experienced fewer muscle cramps,
tightness, strains, and total injuries in 72 collegiate football
players, [141] fewer total injuries but no differences in
other variables in 39 collegiate baseball players [142], and
fewer muscle cramps but no differences in other variables
in 130 collegiate football players [143]. In these three
studies, creatine ingestion was typical of high-dose loading
followed by low-dose maintenance supplementation pro-
tocols and lasted from one to three seasons. These data
indicate that, in hard-training athletes, creatine may reduce
the likelihood of muscle injury and dysfunction. The
effects of creatine supplementation on muscle injury and
muscle dysfunction are summarized in Table 2 [141–143].
4.8 Creatine Supplementation and Case Studies
of Rhabdomyolysis
We are aware of six cases of individuals who presented
with rhabdomyolysis and were also ingesting creatine
[23, 144–146]. While the number of cases relative to the
number of individuals ingesting creatine supplements is
small, it would be important to identify whether creatine
supplementation was an independent factor that precipi-
tated rhabdomyolysis, was a tipping point (perhaps allow-
ing for more contractions/high intensity) in a person
already at risk with proven factors (heat, dehydration,
NSAID use), or was merely a coincident factor. All of the
individuals were adult males (21–33 years) and five of six
presented with rhabdomyolysis after participating in
extreme unaccustomed exercise (the sixth case was a sur-
gical patient). The involvement of intense exercise indi-
cates exertional rhabdomyolysis rather than creatine
supplement-induced rhabdomyolysis. Four of the men were
ingesting ephedrine, and both dehydration and herbal
diuretic use were also reported, which makes the role of
creatine supplements even more difficult to ascertain. Of
the six cases, four returned to full function, one returned to
partial muscle function, and one died [23]. The fatality was
an obese African American man who had recently lost
weight (17 lbs in 2 weeks), was dehydrated, was ingesting
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natural diuretics and ephedrine, and died at the end of a
2-mile run (army fitness test). Given that all of the cases
above with a reported link to creatine occurred in young
men performing the most common known factor to induce
rhabdomyolysis (unaccustomed, heavy exercise) and some
were taking other drugs accepted by the FDA as being
linked to adverse cardiovascular events (ephedrine), the
link with creatine use is highly tenuous, circumstantial, and
the likely reason why rational scientific evaluations have
not implicated creatine use even in extreme cases of death
after excessive exercise and/or dehydration [127].
Despite the severity of these cases (see Table 3), it
appears that these are typical cases of exertional rhab-
domyolysis. The final case was a patient who presented
with rhabdomyolysis following arthroscopic knee surgery
[146]. The patient, who was described as a college football
player and avid bodybuilder (body mass 100 kg), may have
developed rhabdomyolysis as a result of accepted causes of
rhabdomyolysis: a recent collision with a tree while skiing
(crush syndrome), the tourniquet used during surgery (is-
chemia), NSAID ingestion (intravenous ketorolac), and
pressure on the legs from body positioning during surgery
(ischemia). Although not common, cases of tourniquet-in-
duced rhabdomyolysis are mentioned in the literature
[147–150], including following arthroscopic knee surgery
[146, 151]. Additionally, post-surgery rhabdomyolysis
resulting from pressure on the thighs has been reported and
pressure-induced rhabdomyolysis in obese patients after
bariatric surgery has been reported in patients ingesting
ketorolac [152]. It appears that the patient reported by
Sheth et al. [146] had numerous factors that could have
caused the rhabdomyolysis, including direct muscle injury,
ischemia, and medication.
5 Conclusions
We reviewed the literature on exertional rhabdomyolysis,
identified precipitating factors (e.g., unaccustomed exercise
[especially with eccentric/muscle-lengthening contractions],
ischemia, extreme temperatures, electrolyte abnormalities,
endocrinologic conditions, genetic/autoimmune disorders,
and drugs), and evaluated the role of statins and creatine
supplements in muscle damage and exertional rhabdomyol-
ysis. Healthcare professionals, coaches, and personal trainers
must have the knowledge and expertise to recognize when
exercise is overly strenuous. Furthermore, they should pre-
scribe exercises and use exercise tests that are safe and will
not result in injury. The prevalence of rhabdomyolysis is low
in untrained, athlete, and patient populations, but instances
still occur where exercise is improperly prescribed or used as
punishment, or an incomplete medical history is taken, and
exertional rhabdomyolysis can occur. At a minimum, it
would be beneficial if all parties involved—athletes and
parents, coaches and trainers, and healthcare professionals—
were aware of the basic signs of exertional rhabdomyolysis,
such as extreme pain and brown urine. Then, rather than a
disorganized response and hysterical reaction to what is
viewed as a ‘‘mysterious disease,’’ prompt treatment can be
administered. Better still, as a preventive measure, all coa-
ches and trainers should be educated on the science of
exercise testing and prescription. The design and adminis-
tration of strength and conditioning programs and exercise
fitness testing are supported by many years of research. The
leading sport science organizations, such as the American
College of Sports Medicine and the National Strength and
Conditioning Association have research and applied practi-
tioner journals, position stands, textbooks, professional cer-
tifications, and continuing education opportunities to help
ensure that the science and practice of exercise testing and
prescription is safe and effective.
Regarding creatine supplementation, survey data indi-
cate that creatine monohydrate is a widely used dietary
supplement. For example, a survey of Olympic-caliber
Finnish athletes indicated that 16% (n = 446) used cre-
atine in 2002 and 8% (n = 372) used creatine in 2009
[153]. Creatine use in Canadian Olympians was somewhat
more common during the Atlanta (14%; n = 257) and
Sydney Olympic Games (12%; n = 300) [154]. A greater
prevalence of use was noted in a survey of 133 military
(29%) and 96 civilian (57%) health club members [155]
and in a survey of 203 Division I collegiate athletes (37%)
[156]. The greatest prevalence of use (74%) was reported
in 50 Australian power lifters [157].
Although the prevalence of creatine supplementation is
quite variable (8–74%), it is clear that many thousands of
hard-training individuals are ingesting creatine supple-
ments. If one believed that the link between exertional
rhabdomyolysis and creatine supplementation was more
than coincident, one would also expect that exertional
rhabdomyolysis would occur more frequently in creatine
users. There are no such data. As an example, Alpers and
Jones [54] reported that the incidence of exertional rhab-
domyolysis in military trainees undergoing basic military
training was 22 cases per 100,000 per year (0.02%), while
Sheppard et al. [155] reported that creatine supplement use
in military health clubs was 29%. In fact, given the data
that show a protective effect of creatine on muscle
inflammation, damage, and injury in hard-training indi-
viduals (see Tables 1, 2) and the lack of an obvious
increase in exertional rhabdomyolysis in creatine supple-
ment users, it could be argued that creatine supplements are
protective against exertional rhabdomyolysis. The 15
studies reviewed in Table 1 demonstrate that creatine
supplementation has either no effect on resting, post-re-
sistance exercise, or post-eccentric exercise markers of





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































exercise-induced muscle damage or offers a protective
effect during intense endurance or eccentric exercise. The
data reviewed in Table 2 demonstrate that intensely train-
ing athletes ingesting creatine supplements have similar or
reduced muscle dysfunction or injury. It appears that,
although often described as a precipitating factor for
exertional rhabdomyolysis, there is no evidence to impli-
cate creatine supplementation.
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